NeOnc secures UAE IND clearance for brain tumour drug NEO212
NeOnc Technologies Holdings has received Investigational New Drug authorisation from the Department of Health – Abu Dhabi for NEO212, its orally administered perillyl alcohol-temozolomide conjugate targeting aggressive brain tumours. The clearance, granted in June 2026, marks the first international regulatory approval for the compound and follows completion of the Phase 1 dose-escalation portion of the company's ongoing Phase 1/2 study.
That Phase 1 work established 610 mg as the recommended Phase 2 dose. In heavily pretreated patients with recurrent glioblastoma and brain metastases, NeOnc reported what it described as encouraging early signs of clinical activity, including potential durable disease stabilisation. The company was careful not to frame these as confirmed efficacy signals, and full Phase 2 data will be required before the programme's clinical profile can be properly assessed.
International pathway and conditions
The UAE authorisation does not grant marketing rights and comes with a number of conditions NeOnc must satisfy before it can begin enrolling patients. These include separate approval from the DOH Institutional Review Board, plus amendments to the study protocol, investigator's brochure, and product labelling. The company is also pursuing parallel discussions with the US Food and Drug Administration on the design of a potential registrational pathway for NEO212, and says running multiple regulatory tracks simultaneously is intended to accelerate the overall development timeline.
NeOnc has additionally submitted applications to the Department of Health – Abu Dhabi covering three further programmes, NEO100-01, NEO100-02, and NEO100-03, and is awaiting decisions on each. If approved, those would extend the company's UAE clinical footprint beyond NEO212 alone.
Chief executive Amir Heshmatpour said glioblastoma patients "urgently need new treatment options" and described the Abu Dhabi clearance as an important international milestone. The quote, while genuine in sentiment, reflects standard positioning language for a pre-Phase 2 announcement without approved product data.
Market context and competitive landscape
Glioblastoma remains one of the most treatment-resistant cancers, with median overall survival typically under 15 months from diagnosis. Temozolomide, the chemotherapy agent at the core of NEO212's conjugate structure, has been a standard-of-care backbone since the mid-2000s. NeOnc's approach combines it with perillyl alcohol, a naturally derived compound, in a conjugate designed to cross the blood-brain barrier more effectively than either agent administered separately. The blood-brain barrier problem is a long-standing bottleneck in CNS oncology drug development, and a number of clinical-stage companies are pursuing various strategies to address it, including antibody-drug conjugates, convection-enhanced delivery, and focused ultrasound-mediated permeabilisation.
The UAE has become a modestly active jurisdiction for international clinical trials in oncology, partly because of streamlined timelines within the Abu Dhabi regulatory framework. For small Nasdaq-listed clinical-stage companies, running parallel global programmes can help demonstrate international investor appetite and widen eventual commercial optionality, though it also adds operational and regulatory complexity. NeOnc's patent portfolio, licensed from the University of Southern California, extends to 2038, which offers some commercial runway if either NEO212 or the NEO100 programmes reach approval. Near-term milestones to watch include IRB sign-off in the UAE, progress in FDA dialogue on registrational design, and the first Phase 2 data readout.